Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
23 sept. 2014 09h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 23, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced an out-licensing
agreement for TGR-1202, a novel next generation PI3K-delta
inhibitor. TG...